Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
EMBO Molecular Medicine|June 1, 2018
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancerDana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
The Lancet. Oncology|September 4, 2025
Establishing the China-UK Cancer Prevention and Control AllianceJun Ma, David Kerr, Yuankai Shi, et al.
The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
BMC Cancer|November 19, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocolStephan Ursprung, Helen Mossop, Ferdia A Gallagher, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screeningFiona E McRonald, Ghasem Yadegarfar, David R Baldwin, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
EMBO Molecular Medicine|June 1, 2018
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancerDana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.
The Lancet. Oncology|May 18, 2013
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataAudrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, et al.
The Lancet. Oncology|September 4, 2025
Establishing the China-UK Cancer Prevention and Control AllianceJun Ma, David Kerr, Yuankai Shi, et al.
The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell CarcinomaAndrew J Armstrong, Andrew B Nixon, Andrea Carmack, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
BMC Cancer|November 19, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocolStephan Ursprung, Helen Mossop, Ferdia A Gallagher, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screeningFiona E McRonald, Ghasem Yadegarfar, David R Baldwin, et al.
Pageof 12